Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Admilparant in adults with pulmonary fibrosis
MOH_2026-05-19_015835Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of admilparant in pulmonary fibrosis (PF) and idiopathic pulmonary fibrosis (IPF), sponsored by Bristol Myers Squibb. Planned start May 2026; status: not yet recruiting.
02
Drugs
admilparant
03
Conditions
pulmonary fibrosis (PF)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2026-05-19_015835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-19_015835.